

Special Issue

Computational Pathology for Breast Cancer and Gynecologic Cancer

Message from the Guest Editor

Computational pathology is growing in cancer, including diagnosis, phenotyping, subtype classification, early detection, prognostication, assessment of sensitivity to chemotherapy and immunotherapy, and identification of suitable targeted therapies. Several studies have reported on the utility of computational imaging to automate cancer diagnoses without compromising accuracy. Another study of the quantitative characterization of the architecture of tumor-infiltrating lymphocytes and their interplay with cancer cells from H&E slides of three different gynecologic cancer types (ovarian, cervical, and endometrial) and across three different treatment approaches (platinum, radiation, and immunotherapy) showed that the geospatial profile was prognostic of disease progression and survival, irrespective of the treatment modality. This Special Issue will summarize the recent developments in computational pathology in cancer. It will interpret the complexity of computational pathology for breast cancer and gynecologic cancer. Purely computational/informatics (analysis) papers should include sufficient experimental validation.

Guest Editor

Prof. Dr. Ching-Wei Wang
Graduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan

Deadline for manuscript submissions

closed (31 March 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/155369

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)